Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioInvent International AB (BOVNF) Fair Value & Analysis

Healthcare · US · Market cap $216M

Price$3.29
Fair Value$3.89
Upside+18.3%
Quality95/100
Evidence: Low Range $2.92 – $4.87

Fair value as of: Jun 24, 2026

Analysis

BioInvent International AB (BOVNF) currently trades at $3.29, while our model-based Fair Value estimate is $3.89 — implying the stock looks roughly 18.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda;…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is BioInvent International AB (BOVNF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.89 versus a price of $3.29 — about +18% (undervalued). Model-based estimate, not financial advice.
What is the fair value of BOVNF?
Our 21-model fair value for BioInvent International AB is $3.89 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.29.
What is the quality score of BOVNF?
BioInvent International AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.